Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas.
The appointment of a dedicated executive to lead the Company’s long-term strategy in the Americas is indicative of the growing regional demand trends and the Company’s commitment to broaden its footprint, accelerate its market penetration and improve proximity to its customers in this important region.
“We are excited to welcome Riccardo Butta to Stevanato Group”, said Franco Moro, CEO of Stevanato Group. “We believe the Americas represent a significant growth opportunity for our company, and we are confident that Riccardo’s deep commercial, operational and management expertise will help us strengthen our presence and advance our strategic priorities in this important region.”
Riccardo Butta, President, Americas, commented: “I look forward to working with this talented leadership team to expand our presence and market share in the Americas, while continuing Stevanato Group’s mission to serve its customers through an integrated approach, from design and development through to commercialization.”
Riccardo Butta joins the Group with more than 30 years of management experience, including 20 years with Flex Ltd., an industry-leading contract development and manufacturing organization with operations spanning 30 countries, including a large presence in the U.S. and Mexico. In his most recent role as Senior Vice President, Riccardo was responsible for the global commercial organization of Flex Health Solutions, a business unit of Flex providing contract design, manufacturing, and logistics services to the healthcare industry with a focus on medical devices, drug delivery solutions, and medical/life sciences equipment. During his tenure at Flex, Riccardo was also responsible for the European organization of Flex Health Solutions, for the global engineering organization focused on medical device development, and for scaling up the Milan medical design center.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.
02.02.2022, Stevanato
Материал новостей на Сайте - авторское право и принадлежит Компании или третьему лицу, поставщику новостей , и все права сохранены. Любой Пользователь, который получает доступ к такому материалу, может делать это только в целях собственного использования, и использование такого материала - риск для самого Пользователя. Перераспределение или другая коммерческая эксплуатация такого материала новостей явно запрещены. Где такой материал новостей обеспечен третьим лицом, каждый Пользователь соглашается наблюдать и быть связанным определенными условиями использования, относящимися к такому материалу новостей. Мы не представляем или подтверждаем точность, или надежность любой информации содержащейся в любых новостях или внешних веб-сайтах, упомянутых в новостях.
Если содержание или оформление этих станиц нарушает права третьих лиц или положения закона, тогда мы просим о соответствующем уведомлении без необходимых издержек. Я ручаюсь, что по праву вызванное недовольство место в тексте будет незамедлительно удалено, не требуя подключения поверенного лица с Вашей стороны. Однако вызванные Вами расходы без преждевременного установления конакта будут нами в полной мере отклонены и при необходимости мы подадим встречную жалобу касательно нарушения вышеназванных положений.